GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » KPC Pharmaceuticals Inc (SHSE:600422) » Definitions » Gross Margin %

KPC Pharmaceuticals (SHSE:600422) Gross Margin % : 36.91% (As of Mar. 2025)


View and export this data going back to 2000. Start your Free Trial

What is KPC Pharmaceuticals Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. KPC Pharmaceuticals's Gross Profit for the three months ended in Mar. 2025 was ¥594 Mil. KPC Pharmaceuticals's Revenue for the three months ended in Mar. 2025 was ¥1,608 Mil. Therefore, KPC Pharmaceuticals's Gross Margin % for the quarter that ended in Mar. 2025 was 36.91%.


The historical rank and industry rank for KPC Pharmaceuticals's Gross Margin % or its related term are showing as below:

SHSE:600422' s Gross Margin % Range Over the Past 10 Years
Min: 34.5   Med: 43.31   Max: 49.89
Current: 42.35


During the past 13 years, the highest Gross Margin % of KPC Pharmaceuticals was 49.89%. The lowest was 34.50%. And the median was 43.31%.

SHSE:600422's Gross Margin % is ranked worse than
60.34% of 948 companies
in the Drug Manufacturers industry
Industry Median: 47.205 vs SHSE:600422: 42.35

KPC Pharmaceuticals had a gross margin of 36.91% for the quarter that ended in Mar. 2025 => Competition eroding margins

The 5-Year average Growth Rate of Gross Margin for KPC Pharmaceuticals was -0.90% per year.


KPC Pharmaceuticals Gross Margin % Historical Data

The historical data trend for KPC Pharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KPC Pharmaceuticals Gross Margin % Chart

KPC Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.16 41.30 41.52 46.61 43.46

KPC Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.66 39.26 40.55 48.18 36.91

Competitive Comparison of KPC Pharmaceuticals's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, KPC Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


KPC Pharmaceuticals's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, KPC Pharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where KPC Pharmaceuticals's Gross Margin % falls into.


;
;

KPC Pharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

KPC Pharmaceuticals's Gross Margin for the fiscal year that ended in Dec. 2024 is calculated as

Gross Margin % (A: Dec. 2024 )=Gross Profit (A: Dec. 2024 ) / Revenue (A: Dec. 2024 )
=3651.3 / 8401.447
=(Revenue - Cost of Goods Sold) / Revenue
=(8401.447 - 4750.196) / 8401.447
=43.46 %

KPC Pharmaceuticals's Gross Margin for the quarter that ended in Mar. 2025 is calculated as


Gross Margin % (Q: Mar. 2025 )=Gross Profit (Q: Mar. 2025 ) / Revenue (Q: Mar. 2025 )
=593.7 / 1608.452
=(Revenue - Cost of Goods Sold) / Revenue
=(1608.452 - 1014.74) / 1608.452
=36.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


KPC Pharmaceuticals  (SHSE:600422) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

KPC Pharmaceuticals had a gross margin of 36.91% for the quarter that ended in Mar. 2025 => Competition eroding margins


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


KPC Pharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of KPC Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


KPC Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
No. 166 Keyi Road, State New and High-Technology Development Zone, Kunming, Yunnan, CHN, 650106
KPC Pharmaceuticals Inc is a pharmaceutical company which focused on innovative natural botanical drugs in China. Its business scope covers traditional Chinese medicine, chemical medicine, and medicinal circulation. Its products include Panax notoginseng, gastrodine, artemether, and special botanical drugs.
Executives
Qu Xiao Ru senior management
Xie Bo senior management
Meng Li senior management
Zhong Xiang Gang senior management
Wu Sheng Long senior management
Liu Jun Feng senior management
Wang Lei senior management
Zhang Meng Xun senior management
Hu Zhen Bo senior management
Sun Lei senior management
Xu Chao Neng senior management
Wang Jun senior management
Zhao Jian senior management
He Qin Director
Dai Xiao Chang senior management

KPC Pharmaceuticals Headlines

No Headlines